307M-9
Cytokeratin 7 (OV-TL 12/30) Mouse Monoclonal Antibody
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
OV-TL 12/30, monoclonal
Application:
IHC (p)
Citations:
10
biological source
mouse
conjugate
unconjugated
antibody form
diluted ascites fluid
antibody product type
primary antibodies
clone
OV-TL 12/30, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (307M-94), vial of 0.5 mL concentrate (307M-95), bottle of 1.0 mL predilute (307M-97), vial of 1.0 mL concentrate (307M-96), bottle of 7.0 mL predilute (307M-98)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
isotype
IgG1κ
control
lung adenocarcinoma
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic
Gene Information
human ... KRT7(3855)
General description
Anti-cytokeratin 7 reacts with proteins that are found in most ductal, glandular, transitional, and biliary duct epithelial cells. Cytokeratin 7 (CK7) labeling can help distinguish between lung, breast carcinomas, and urothelial carcinomas that are typically stain positive, and colon and prostate carcinomas that typically lack CK7 expression. CK7 is a common marker of primary lung adenocarcinomas and is observed in other primary lung carcinomas and non-pulmonary carcinomas. Anti-cytokeratin 7 has also been useful in the differential diagnosis of ovarianneoplasms.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
 IVD |  IVD |  IVD |  RUO |
Other Notes
Cytokeratin 7 Positive Control Slides, Product No. 307S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Shawn K Murray et al.
The American journal of surgical pathology, 28(9), 1154-1162 (2004-08-19)
We recently identified metastatic prostate carcinoma (PCA) within perirectal lymph nodes (PLNs) from 2 patients undergoing abdominoperineal resection (APR) for rectal adenocarcinoma (RA). As this phenomenon has not been addressed by any studies in the literature and because these positive
Preetha Ramalingam et al.
Annals of diagnostic pathology, 7(2), 112-119 (2003-04-26)
Carcinomas with micropapillary features have been described in the breast, urinary bladder, lung, and ovary. They are characterized by the presence of micropapillary tufts in clear spaces. Unequivocal vascular invasion is usually present at the periphery of the tumor. Consequently
W G McCluggage et al.
Histopathology, 47(3), 231-247 (2005-08-24)
The ovary is a common site of metastatic tumour. In many cases of ovarian metastasis there is a known history of malignancy but in other cases the ovarian tumour is the first manifestation of disease. In this review metastatic colorectal